Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended 30th June, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting with Unaudited Financial Results
Audit Opinion:
Clean opinion - Limited review report states nothing has come to their attention that causes them to believe the financial results contain any material misstatement.
Key Financial Highlights [Rs. In Lakh]:
Standalone Results:
Revenue from Operations: ₹7297.25 lakh (Q1 FY27) vs ₹7109.70 lakh (Q4 FY26) - Increase of ₹187.55 lakh
Total Income: ₹7451.64 lakh (Q1 FY27) vs ₹7126.82 lakh (Q4 FY26)
EBITDA: Not explicitly disclosed
Net Profit: ₹1028.49 lakh (Q1 FY27) vs ₹1102.43 lakh (Q4 FY26) - Decrease of ₹73.94 lakh
EPS: ₹4.62 (Basic and Diluted) for Q1 FY27 vs ₹4.96 for Q4 FY26
Other Equity: Not specified for current quarter
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Consolidated Results:
Revenue from Operations: ₹7297.25 lakh (Q1 FY27) vs ₹7109.70 lakh (Q4 FY26)
Total Income: ₹7451.64 lakh (Q1 FY27) vs ₹7126.82 lakh (Q4 FY26)
Net Profit: ₹1028.49 lakh (Attributable to owners) vs ₹1102.43 lakh (Q4 FY26)
EPS: ₹4.62 (Basic and Diluted) for Q1 FY27 vs ₹4.96 for Q4 FY26
Note: Consolidated figures are identical to standalone figures as subsidiary Sakar Oncology Private Limited has not carried out any business transactions during the reporting period.
Segment-wise Performance:
The Company operates only in one segment: Manufacturing of Pharmaceutical Products including Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not provided.
Corporate Actions:
No dividend declarations, share splits, bonus issues, buybacks, or capital structure changes announced.
No capital raising activities announced.
Director or Auditor Appointments:
- Appointment of M/s. Kashyap R. Mehta & Partners, Practising Company Secretaries (FRN: P2025GJ106000) as Secretarial Auditors for five consecutive years commencing from FY 2026-27 to 2030-31, subject to shareholders' approval at 22nd AGM.
- Appointment of M/s. Dalwadi & Associates, Cost Accountants, Ahmedabad (Firm Registration No. 000338) as Cost Auditors for the financial year 2026-27.
Other Regulatory Information:
- No deviations in proceeds of public issue
- No outstanding defaults on loans and debt securities
- Total financial indebtedness: ₹0
- No related party transactions requiring disclosure for half-year
- No audit qualifications impacting financial results
Other Significant Information:
Annual General Meeting:
- 22nd Annual General Meeting scheduled for Tuesday, 22nd September, 2026 at 12:30 p.m. through Video Conferencing / Other Audio Visual Means
- Remote e-voting period: Commences at 9:00 a.m. on 19th September, 2026
- E-voting during AGM allowed until 15 minutes after conclusion of AGM
Subsidiary Information:
- Wholly owned subsidiary: Sakar Oncology Private Limited
- Subsidiary has not carried out any business transactions during the relevant reporting period
Accounting Policies:
- Financial results prepared in accordance with Indian Accounting Standards (Ind AS)
- Provision for taxation/deferred taxation will be made at year end
- Figures regrouped/rearranged where required